Abstract
Postmenopausal osteoporosis has long-term physical, psychological, and social consequences with a major impact on patients’ daily life. Treatment for such a chronic disease needs to be clinically effective and well tolerated, and should ultimately result in a beneficial effect on quality of life. The antifracture efficacy of strontium ranelate, 2 g/day orally, an agent that appears to have dissociation effects on resorption and formation, has been assessed in two large, randomized, double-blind, placebo-controlled clinical studies: the Spinal Osteoporosis Therapeutic Intervention (SOTI) trial and the TReatment Of Peripheral Osteoporosis Study (TROPOS), including more than 6,700 postmenopausal women. Pending the results of TROPOS, a 3-year analysis of SOTI results shows that strontium ranelate significantly reduces new vertebral and clinical vertebral fracture incidence in postmenopausal osteoporotic women. This significant reduction in the risk of clinical and new vertebral fractures has been demonstrated as early as after 1 year of treatment (RR=0.48, p=0.003; and RR=0.51, p<0.001, respectively) and is maintained over 3 years (RR=0.62, p<0.001; and RR=0.59, p<0.001, respectively). This is accompanied by decreased back pain and body height loss in the strontium ranelate group compared with the placebo group. As strontium ranelate appears to improve clinical signs and is, furthermore, well tolerated especially in the upper gastrointestinal region, this treatment is expected to result in an improved health-related quality of life (HRQoL). Strontium ranelate thus offers significant clinical benefits in terms of efficacy, tolerability, and ease of administration in the treatment of postmenopausal women with vertebral osteoporotic fractures.
Similar content being viewed by others
Abbreviations
- BMD:
-
Bone mineral density
- CI:
-
Confidence interval
- HRQoL:
-
Health-related quality of life
- ITT:
-
Intention to treat
- RR:
-
Relative risk
References
O’Neill TW, Roy DK (2003) The epidemiology and scale of the problem. Hosp Med 64(9):517–520
Truumees E (2003) Medical consequences of osteoporotic vertebral compression fractures. Instr Course Lect 52:551–558
Hawker GA (1996) The epidemiology of osteoporosis. J Rheumatol Suppl 45:2–5
Gold DT (2003) Osteoporosis and quality of life psychosocial outcomes and interventions for individual patients. Clin Geriatr Med 19(2):271–280
Martin AR, Sornay-Rendu E, Chandler JM, Duboeuf F, Girman CJ, Delmas PD (2002) The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 31:32–36
Marie PJ, Ammann P, Boivin G, Rey C (2001) Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121–129
Reginster JY (2002) Strontium ranelate in osteoporosis. Curr Pharm Des 8:1907–1916
Reginster JY, Deroisy R, Jupsin I (2003) Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today (Barc) 39:89–101
Meunier PJ, Reginster JY (2003) Design and methodology of the phase III trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 14[Suppl 3]:S66–S76
Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–68
Silverman SL, Minshall ME, Shen W, Harper KD, Xie S (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619
Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392
Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11:460–466
Cohen-Solal ME, de Vernejoul MC (2002) Quality of life in osteoporosis. Medicographia 24:349–352
Osteoporosis Quality of Life Study Group (1997) Measuring quality of life in women with osteoporosis. Osteoporos Int 7:478–487
Helmes E, Hodsman A, Lazowski D, Bhardwaj A, Crilly R, Nichol P, Drost D, Vanderburgh L, Pederson L (1995) A questionnaire to evaluate disability in osteoporotic patients with vertebral compression fractures. J Gerontol A Biol Sci Med Sci 50:M91–M98
Marquis P, Cialdella P, De la Loge C (2001) Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res 10:555–566
Tosteson AN, Hammond CS (2002). Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 20:289–303
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delmas, P.D. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis. Osteoporos Int 16 (Suppl 1), S16–S19 (2005). https://doi.org/10.1007/s00198-004-1767-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-004-1767-2